6-K: Report of foreign private issuer (related to financial reporting)
6-K: Report of foreign private issuer (related to financial reporting)
6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A
6-K: Colletion of Recent Announcements
11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)
11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)
6-K: Colletion of Recent Announcements
SC 13G: Statement of acquisition of beneficial ownership by individuals-Sanofi(8.0%)
6-K: Sanofi Completes Acquisition of Inhibrx, Inc
6-K: Colletion of Recent Announcements
SD: Specialized disclosure report
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Sanofi Q1 Robust 7% Sales Growth Driven by Launches, Underpins Full-Year Guidance
UPLOAD: Others
CORRESP: CORRESP
UPLOAD: Others
SANOFI | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
SANOFI | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
No Data